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Purpose. The aim of this study was to assess the safety and tolerability of motesanib (an orally administered small-molecule
antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and Kit) when
administered in combination with panitumumab, gemcitabine, and cisplatin. Methods. This was an open-label, multicenter phase
1b study in patients with advanced solid tumors with an ECOG performance status ≤1 and for whom a gemcitabine/cisplatin
regimen was indicated. Patients received motesanib (0mg [control], 50mg once daily [QD], 75mg QD, 100mg QD, 125mg QD,
or 75mg twice daily [BID]) with panitumumab (9mg/kg), gemcitabine (1250mg/m2)a n dc i s p l a t i n( 7 5m g / m 2) in 21-day cycles.
The primary endpoint was the incidence of dose-limiting toxicities (DLTs). Results. Forty-one patients were enrolled and received
treatment (including 8 control patients). One of eight patients in the 50mg QD cohort and 5/11 patients in the 125mg QD
cohort experienced DLTs. The maximum tolerated dose was established as 100mg QD. Among patients who received motesanib
(n = 33), 29 had motesanib-related adverse events. Fourteen patients had serious motesanib-related events. Ten patients had
motesanib-related venous thromboembolic events and three had motesanib-related arterial thromboembolic events, two of which
were considered serious. One patient had a complete response and nine had partial responses as their best objective response.
Conclusions. The combination of motesanib, panitumumab, and gemcitabine/cisplatin could not be administered consistently
and, at the described doses and schedule, may be intolerable. However, encouraging antitumor activity was noted in some cases.
1.Introduction
Agents that inhibit angiogenesis, the process by which new
blood vessels develop, have emerged as a viable treatment
option for patients with solid tumors [1, 2]. In clinical
studies, the most eﬀective antiangiogenic agents tested thus
far are those targeting either vascular endothelial growth
factor (VEGF), which plays a crucial, rate-limiting role in
angiogenesis [3], or its receptors VEGFR1 and VEGFR2
[1, 4–6]. Two other receptor tyrosine kinases, platelet-
derived growth factor receptor (PDGFR) and stem cell factor
receptor (Kit), have also been implicated in the pathogenesis
of a variety of tumor types [7, 8]. Agents inhibiting these
receptorshavebeenshowntohaveantitumoreﬃcacy[9,10].
Recent studies suggest that treatment with a VEGF
inhibitor in combination with cytotoxic chemotherapy
and/or other targeted anticancer therapies may result in
increased activity against solid tumors compared with
monotherapy while maintaining an acceptable tolerability
proﬁle. Combining the monoclonal anti-VEGF antibody
bevacizumab with carboplatin/paclitaxel resulted in longer
survival time compared with chemotherapy treatment alone2 Journal of Oncology
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Figure 1: Study schema.
in patients with non–small-cell lung cancer (NSCLC) [6].
Epidermal growth factor receptor (EGFR) is another rec-
ognized target for cancer treatment. In NSCLC, treatment
with the anti-EGFR monoclonal antibody cetuximab in
combination with cisplatin/vinorelbine resulted in improved
overall survival compared with cisplatin/vinorelbine alone
[11]. In a study in advanced NSCLC, the 1-year survival rate
of patients receiving bevacizumab plus the EGFR inhibitor
erlotinib was similar to that observed in those treated
with bevacizumab and chemotherapy [12]. In each of these
studies, the addition of a targeted agent was superior to
chemotherapy alone.
Motesanib is an orally administered small-molecule
antagonist of VEGFR1, 2, and 3 (50% inhibitory concen-
tration [IC50] = 2,3,6nM, resp.), of PDGFR (84nM),
and Kit (8nM) [13]. Motesanib has shown encouraging
eﬃcacy and acceptable toxicity as a monotherapy [14–16]
or in combination with standard chemotherapy regimen
[17–19]. The primary objective of the present study was to
determinethemaximumtolerateddose(MTD)ofmotesanib
when administered in combination with the fully human
anti-EGFR monoclonal antibody panitumumab, which is
approved for the treatment of metastatic colorectal cancer,
andthechemotherapiesgemcitabineandcisplatininpatients
with advanced solid tumors. The pharmacokinetics of each
agent as well as the safety and eﬃcacy of this treatment
regimen were also assessed.
2. Methods
2.1. Patients. Eligible patients were ≥18 years of age, had
advanced cancer for which a gemcitabine/cisplatin regi-
men was clinically indicated, had an Eastern Cooperative
Oncology Group performance status of 0 or 1, and had
adequate cardiac, renal, and hepatic function. Patients with a
history of another primary cancer were eligible if the cancer
had been curatively treated with no known active disease
or treatment in the 3 years before study enrollment. Key
exclusion criteria were central nervous system metastases;
history of arterial or venous thrombosis, pulmonary hem-
orrhage, or gross hemoptysis; uncontrolled hypertension
(average systolic blood pressure >145mmHg or average
diastolic blood pressure >85mmHg); myocardial infarction,
cerebrovascular accident, transient ischemic attack, coronary
angioplasty/stent, or unstable angina within 1 year of study
enrollment; prior treatment with oral inhibitors of VEGF or
anti-EGFR monoclonal antibodies; systemic chemotherapy
within 28 days or radiation therapy for peripheral lesions
within 14 days of enrollment; concurrent treatment with
potent cytochrome P 450 3A inhibitors; absolute neutrophil
count<1.5×109/L;plateletcount<100×109/L;hemoglobin
<9g/dL; aspartate aminotransferase (AST) >2.5×the upper
limit of normal (ULN); alanine aminotransferase (ALT)
>2.5×ULN; alkaline phosphatase >2.0×ULN. All patients
provided written informed consent.
2.2. Study Design. This was a two-part open-label, phase 1b,
multicenter, sequential dose escalation study of motesanib
plus panitumumab (Amgen Inc., Thousand Oaks, Calif,
USA) and gemcitabine/cisplatin in patients with advanced
solid tumors. Part 1 assessed the safety and tolerability of
motesanib when administered in combination with panitu-
mumab and gemcitabine/cisplatin. Patients enrolled in Part
2weretreatedwithmotesanibattheMTDestablishedinPart
1( Figure 1). Eligibility criteria for Parts 1 and 2 were the
same. The primary endpoint of Part 1 was the incidence of
dose-limiting toxicities (DLT) as described below. Secondary
endpoints included the incidence of adverse events and
clinical laboratory abnormalities; the pharmacokinetics of
motesanib when administered in combination with panitu-
mumab and gemcitabine/cisplatin; and eﬃcacy as assessed
by modiﬁed Response Evaluation Criteria in Solid Tumors
(RECIST) criteria [20]. The primary endpoint of Part 2
was the response rate at the MTD established in Part 1.
All study procedures were approved by each study center’s
independent ethics committee or Institutional Review Board
and were consistent with the Declaration of Helsinki.
2.3. Dose Escalation and Treatment. All patients received
panitumumab and gemcitabine/cisplatin as described below.
Motesanib was orally administered once daily (QD) or twice
daily (BID) beginning on day 1 of treatment cycle 1 ﬁrst
thing in the morning on an empty stomach; patients were to
refrain from eating for an hour after taking motesanib. Based
on the tolerable doses established in a previous motesanibJournal of Oncology 3
monotherapy study [14], patients in Part 1 of the study
were enrolled in sequential cohorts of at least four to six
patients each, receiving doses of 0mg, 50mgQD, 75mgQD,
100mgQD, 125mgQD, or 75mgBID (Figure 1). If one of
the initial four enrolled patients experienced a DLT, two
additional patients were enrolled in that cohort. The dose
cohortscouldbeexpanded,ifnecessary,toacquireadditional
safety or pharmacokinetic data or if the MTD was not
established from the initial number of patients enrolled.
Enrollment in the next cohort opened if the initial four
enrolled patients completed the ﬁrst treatment cycle without
experiencing a DLT or if fewer than two of the initial six
patients experienced a DLT.
Patients received 9mg/kg panitumumab by intravenous
infusion on day 1 of each cycle. Panitumumab was admin-
istered until intolerability or disease progression developed.
Gemcitabine was administered on day 1 and day 8 (±1
day) of each cycle at a dose of 1250mg/m2. Cisplatin was
administeredonday1ofeachcycleatadoseof75mg/m2.All
treatment cycles were 21 days long, and additional time was
allowed to recover from toxicity if necessary. Administration
of panitumumab, motesanib, gemcitabine, and cisplatin
continued until disease progression or unacceptable toxicity
precluded further treatment.
Doses of motesanib, panitumumab, gemcitabine, and
cisplatin could be withheld, modiﬁed, or delayed per study
protocol-speciﬁedrulesbasedontheoccurrenceoftoxicities.
2.4. Dose-Limiting Toxicities and Maximum Tolerated Dose.
Dose-limiting toxicity was deﬁned as grade 3 fatigue per-
sisting for ≥7d a y so rg r a d e4f a t i g u e ;g r a d e3o r4
nausea, diarrhea, or vomiting despite maximum supportive
care; symptomatic pulmonary embolism (incidental asymp-
tomatic pulmonary embolism or deep vein thrombosis
identiﬁed during routine tumor imaging procedures was not
DLTs); grade 3 or 4 neutropenia with fever >38.5◦C; grade
4 neutropenia (absolute neutrophil count <0.5×109/L) or
thrombocytopenia (platelet count <25×109/L) for >7d a y s ;
grade 4 hypertension; grade 4 rash/desquamation; grade 4
hypertension; AST or ALT >10×ULN; symptomatic hypo-
magnesemia despite intravenous magnesium replacement;
any other motesanib- and/or panitumumab-related grade 4
hematologic or grade 3 nonhematologic toxicity that was
unacceptable in duration during the DLT period (cycle 1).
The MTD was deﬁned as the highest well-tolerated dose
of motesanib when coadministered with panitumumab and
gemcitabine/cisplatin.
2.5. Safety. Adverse events were recorded throughout the
study and graded (including DLTs) according to the Com-
mon Terminology Criteria for Adverse Events, version 3.0.
Samples for assessment of hematology, blood chemistry,
urinalysis, and thyroid function were collected on day 1 of
each cycle.
2.6. Pharmacokinetic Analyses. Plasma samples for intensive
pharmacokinetic analysis of motesanib were collected before
dose, at 1, 3, 6, and 12 hours (BID cohorts only), and at 24
hours after dose on day 1 of cycle 1. In addition, predose
plasma samples for motesanib were collected on day 1 of
cycles 2 and 3. Serum samples for analysis of panitumumab
concentration were collected before dose and 30 minutes
after the completion of infusion on day 1 of cycles 1, 2, and
4. Plasma samples for analysis of gemcitabine/cisplatin were
collected at the completion of gemcitabine infusion on days
1 and 8 of cycles 1 and 2 and at the completion of cisplatin
infusion on day 1 of cycles 1 and 2.
Plasma motesanib and gemcitabine concentrations were
analyzed using a validated liquid chromatography/tandem
mass spectrometry (LC-MS/MS) method, respectively.
Serum panitumumab concentrations were assessed by an
enzyme-linked immunosorbent assay. Total and free plat-
inum (administered as cisplatin) were measured by vali-
dated, inductively coupled plasma mass spectrometry (MDS
Pharma Services, Lincoln, Neb, USA). All pharmacokinetic
parameterestimateswerecalculatedusingstandardnoncom-
partmental methods and WinNonlin Professional software
on Citrix (Version 5.1.1, Pharsight Corporation, Mountain
View, Calif, USA).
2.7. Eﬃcacy Analysis. Magnetic resonance imaging or com-
puted tomographic scans were performed at baseline and
every 6 to 9 weeks throughout the study. Any ﬁnding of
complete or partial response was conﬁrmed between 4 and
6 weeks after the initial determination of complete or partial
response. Target lesions were evaluated by the investigator
using modiﬁed RECIST [20].
2.8. Statistical Analysis. All patients who received at least one
dose of motesanib, panitumumab, or gemcitabine/cisplatin
were included in the safety and eﬃcacy analysis set. The
pharmacokinetic analysis set included patients with evalu-
able pharmacokinetic samples.
3. Results
3.1. Patients. A total of 41 patients were enrolled in the
study and received treatment with motesanib (except those
in the 0-mgQD cohort; n = 8), panitumumab, and
gemcitabine/cisplatin. Demographic and baseline character-
istics are summarized in Table 1. The most common tumor
type was NSCLC (51%), followed by pancreatic (12%).
Almost all patients had stage IV disease (35, 85%), ﬁve
patients had stage III disease, and one patient had stage II
disease.Seventy-sixpercentofpatientshadnotreceivedprior
chemotherapy, and 63% had not received prior radiation
therapy. The median number of days on which motesanib
was administered was 87 (range: 2–453). Patients received
a median of six panitumumab infusions (range: 1–20),
10 gemcitabine infusions (range: 1–44), and ﬁve cisplatin
infusions (range: 1–11). Median follow-up time (from the
date of enrollment to the last on-study or long-term follow-
up visit) was 24 weeks (range: 3–73). The ﬁrst patient was
enrolled in December 2004 and the last patient completed
follow-up in May 2007. All patients discontinued treatment
with motesanib and panitumumab; the most common4 Journal of Oncology
Table 1: Demographic and baseline clinical characteristics of study patients.
Motesanib dose cohort
0mgQD
(n = 8)
50mgQD
(n = 8)
75mgQD
(n = 6)
100mgQD
(n = 6)
125mgQD
(n = 11)
75mgBID
(n = 2)
Female, n (%) 4 (50) 3 (38) 2 (33) 4 (67) 5 (45) 0 (0)
Male, n (%) 4 (50) 5 (62) 4 (67) 2 (33) 6 (55) 2 (100)
Race, n (%)
White 6 (75) 7 (88) 4 (67) 6 (100) 11 (100) 2 (100)
Black 1 (13) 1 (13) 2 (33) 0 (0) 0 (0) 0 (0)
Hispanic or Latino 1 (13) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Median age, y (range) 52 (40–72) 65.5 (32–73) 57 (36–73) 52.5 (36–72) 63 (42–70) 65 (53–77)
ECOG performance status, n (%)
0 6 (75) 3 (38) 1 (17) 5 (83) 6 (55) 1 (50)
1 2 (25) 5 (63) 5 (83) 1 (17) 5 (45) 1 (50)
Tumor type, n (%)
Non–small-cell lung 3 (38) 5 (63) 3 (50) 4 (67) 4 (36) 2 (100)
Pancreatic 3 (38) 0 (0) 0 (0) 0 (0) 2 (18) 0 (0)
Esophageal 1 (13) 1 (13) 1 (17) 0 (0) 0 (0) 0 (0)
Bladder 0 (0) 0 (0) 0 (0) 0 (0) 2 (18) 0 (0)
Breast 0 (0) 0 (0) 0 (0) 2 (33) 0 (0) 0 (0)
Kidney 0 (0) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0)
Ovarian 1 (13) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other 0 (0) 1 (13) 0 (0) 0 (0) 2 (18) 0 (0)
Unknown 0 (0) 1 (13) 2 (33) 0 (0) 0 (0) 0 (0)
Number of sites of disease, n (%)a
0 1 (13) 1 (13) 1 (17) 0 (0) 1 (9) 0 (0)
1 3 (38) 2 (25) 1 (17) 3 (50) 3 (27) 1 (50)
2 4 (50) 5 (63) 3 (50) 2 (33) 5 (45) 1 (50)
3 0 (0) 0 (0) 1 (17) 1 (17) 2 (18) 0 (0)
Prior chemotherapy, n (%)
0 6 (75) 4 (50) 5 (83) 4 (67) 10 (91) 2 (100)
1 2 (25) 4 (50) 1 (17) 2 (33) 1 (9) 0 (0)
Prior radiation therapy, n (%)
0 6 (75) 3 (38) 4 (67) 4 (67) 8 (73) 1 (50)
1 0 (0) 4 (50) 1 (17) 1 (17) 3 (27) 0 (0)
2 2 (25) 1 (13) 1 (17) 1 (17) 0 (0) 1 (50)
3 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
BID: twice daily; ECOG: Eastern Cooperative Oncology Group; QD: once daily.
aAs assessed by investigator.
reasons were adverse events (n = 13 and n = 11 patients,
resp.) and disease progression (n = 8a n dn = 10 patients,
resp.).
3.2. Dose Escalation, Dose-Limiting Toxicities, and Maximum
Tolerated Dose. Initially, four patients were enrolled in the
50-mgQD dose cohort. One patient had a DLT of grade
5 pulmonary embolism and died two days after the event.
Subsequently, the cohort was expanded to six and later
to eight patients in order to acquire additional safety
data. No other DLTs occurred in this cohort. Six patients
were then enrolled in the 75-mgQD cohort. No DLTs
were observed. The next dose cohort (100mgQD) again
enrolled six patients. No DLTs occurred and dose escalation
continued. Six patients were then initially enrolled in the
125-mgQD dose cohort. One patient had a DLT of grade
3 confusional state (lasting 4 days). In order to determine
the motesanib MTD six additional patients were planned
to be enrolled in this cohort. After ﬁve more patients had
been added (to bring the total number of enrolled patients to
11), four experienced DLTs: grade 3 diarrhea, dehydration,
and hyponatremia; grade 3 diarrhea, dehydration, and
asthenia; grade 4 fatigue (lasting 4 days); sudden death
(occurring on study day 17). Subsequently, the motesanibJournal of Oncology 5
125-mgQD dose in combination with panitumumab and
gemcitabine/cisplatin was deemed not tolerable, and cohort
enrollment was suspended before the sixth planned patient
was enrolled. The 75-mgBID dose cohort was opened but
enrolled only two patients. No DLTs occurred; however,
the cohort was terminated early because an increased risk
of cholecystitis at this dose had been observed in other
motesanib studies [14, 16, 17]. No patient in the study
describedheredevelopedcholecystitisatanytesteddoselevel
(see below). Based on the incidence of DLTs in the 125-
mgQD cohort, the MTD for motesanib in combination with
panitumumab and gemcitabine/cisplatin was established at
100mgQD.
3.3. Adverse Events. Of the 33 patients who received mote-
sanib, 29 (88%) experienced adverse events considered by
the investigator to be related to motesanib treatment: most
frequently hypertension (n = 15 patients), nausea (n = 15),
fatigue (n = 14), diarrhea (n = 10), anorexia (n = 8), pul-
monary embolism (n = 8), and vomiting (n = 8) (Table 2).
A number of adverse events considered by the investigator
to be related to motesanib treatment that were of speciﬁc
interest occurred, including events that are considered class
eﬀects of VEGF(R) treatment [21], such as hypertension,
thromboembolic events, hemorrhagic events, and neutrope-
nia (Table 2). Cholecystitis and hypothyroidism, which have
been described in other motesanib studies [14–17], did not
occur. One patient in the 100mgQD cohort had grade 3
cholelithiasis and one patient in the 125mgQD cohort had
grade 1 jaundice.
Atotalof10patients(24%)hadvenousthromboembolic
events and three patients (7%) had arterial thromboembolic
events (two of whom had arterial thrombi) related to mote-
sanib treatment (Table 2). These adverse events occurred
across all dose cohorts. Speciﬁcally, eight patients (20%)
had grade 4 or 5 (one patient) pulmonary embolism, four
patients (10%) had deep vein thrombosis (grade 2 or 3),
and one patient (2%) had grade 2 jugular vein thrombosis.
In most patients the venous thromboembolic events were
manageable with anticoagulation therapy without the occur-
rence of a second thromboembolic event. Two patients with
NSCLC had arterial thrombosis (grade 3 and 4, resp.) that
were rated serious.
Fourteen patients (34%) had serious adverse events
considered related to motesanib treatment, most of whom
(n = 8) were enrolled in the 125-mgQD cohort: pulmonary
embolism (n = 3); deep vein thrombosis, dehydration,
and diarrhea (n = 2 each); arterial thrombosis, asthenia,
atrialﬁbrillation,confusionalstate,headache,hyponatremia,
and sudden death (n = 1 each). Six patients (15%)
had at least one motesanib-related serious adverse event
with a worst grade of 4. Five patients died on study. Two
deaths (pulmonary embolism, 50mgQD, and sudden death,
125mgQD) occurred within 30 days of treatment and were
considered by the investigator to be related to motesanib and
panitumumab. The three other deaths were due to disease
progression (n = 2) and hepatic failure and were considered
unrelated to treatment.
Although Part 1 of the study (dose escalation) was
successfully completed, Part 2 was not conducted due to the
high incidence of thromboembolic adverse events observed
in Part 1.
Forty patients (98%) experienced panitumumab-related
adverse events, mostly erythema (n = 25 patients), dermati-
tis acneiform (n = 23), rash (n = 22), nausea (n = 21),
fatigue, (n = 19), pruritus (n = 1 8 ) ,h y p o m a g n e s e m i a( n =
17),diarrhea(n = 16),vomiting(n = 12),anorexia(n = 11),
anemia (n = 7), and dry skin (n = 7). Eleven patients (27%)
had serious panitumumab-related events, most frequently
deep vein thrombosis, dehydration, pulmonary embolism (3
patients, 7% each), and diarrhea (2 patients, 5%). Deep vein
thrombosis and pulmonary embolism were only observed in
patients who also received motesanib. Among the 8 patients
who did not receive motesanib (i.e., those who received
panitumumab and gemcitabine/cisplatin only), the most
frequently occurring panitumumab-related adverse events
were rash (n = 6 ) ,n a u s e a( n = 6), dermatitis acneiform
(n = 5), erythema (n = 5), and pruritus (n = 5).
Thromboembolic events, hemorrhagic events, dehydration,
and hypertension did not occur in these patients.
Twenty patients (49%) had at least one motesanib dose
interruption. In ten of these patients the interruptions were
related to adverse events, and ﬁve of the ten patients had
at least one dose reduction. Panitumumab dose delays and
dose reductions occurred in 21 patients (51%) each. Fifteen
and 20 patients had dose interruptions of gemcitabine and
cisplatin, respectively.
3.4. Pharmacokinetics. Concentration-versus-time proﬁles
and pharmacokinetic parameter estimates for motesanib are
shown in Figure 2 and Table 3, respectively. Motesanib was
rapidly absorbed following oral administration in combina-
tion with panitumumab and gemcitabine-cisplatin. Median
time of maximum observed plasma concentration (tmax)
was approximately 1 hour observed across all dose cohorts.
Mean estimated terminal elimination half-life (t1/2,z)w a s
between5.21and6.72hours,andtherewasnoapparentdose
eﬀect. The mean maximum observed plasma concentration
(Cmax), area under the plasma concentration-versus-time
curve from time 0 to inﬁnite time (AUC0–inf), and observed
concentration at 24 hours after dose (C24)o b s e r v e di n
patients in the 125-mgQD dose cohort were similar to
those observed in a monotherapy study of motesanib [14].
However, for doses below 125mgQD, mean Cmax (but not
AUC0–inf or C24) values were slightly lower compared with
the monotherapy study [14]. Mean daily motesanib C24 was
above the IC50 for human umbilical vein endothelial cell
(HUVEC) proliferation (4ng/mL) [13] in all dose cohorts
and higher than the 90% inhibitory concentration (IC90)f o r
HUVEC proliferation (28ng/mL) in the 125-mgQD and 75-
mgBID dose cohorts.
The serum plasma concentrations of panitumumab,
gemcitabine, and cisplatin are summarized in Table 4.P e a k
and trough serum concentrations of panitumumab were
generally similar across all dose cohorts, although predose
concentrations during cycle 4 were higher in the dose
cohortwithoutmotesanibcomparedwithallmotesanibdose6 Journal of Oncology
Table 2: Patient incidence of motesanib-related adverse events.
Motesanib dose cohort
0mgQD
(n = 8)
50mg QD
(n = 8)
75mg QD
(n = 6)
100mg QD
(n = 6)
125mg QD
(n = 11)
75mgBID
(n = 2)
Patients with any related AE, n (%) 0 (0) 6 (75) 6 (100) 4 (67) 11 (100) 2 (100)
Grade 3 0 (0) 2 (25) 2 (33) 1 (17) 6 (55) 1 (50)
Grade 4 0 (0) 0 (0) 2 (33) 2 (33) 3 (27) 1 (50)
Grade 5 0 (0) 1 (13) 0 (0) 0 (0) 1 (9)a 0( 0 )
Related AEs occurring in ≥10% of
all patients, n (%)
Hypertension 0 (0) 3 (38) 4 (67) 2 (33) 5 (45) 1 (50)
Nausea 0 (0) 4 (50) 5 (83) 2 (33) 4 (36) 0 (0)
Fatigue 0 (0) 4 (50) 2 (33) 2 (33) 6 (55) 0 (0)
Diarrhea 0 (0) 1 (13) 1 (17) 0 (0) 7 (64) 1 (50)
Anorexia 0 (0) 2 (25) 0 (0) 2 (33) 4 (36) 0 (0)
Pulmonary embolism 0 (0) 1 (13) 2 (33) 2 (33) 3 (27) 0 (0)
Vomiting 0 (0) 2 (25) 3 (50) 1 (17) 2 (18) 0 (0)
Dermatitis acneiform 0 (0) 1 (13) 2 (33) 0 (0) 2 (18) 0 (0)
Rash 0 (0) 0 (0) 1 (17) 0 (0) 2 (18) 2 (100)
Constipation 0 (0) 0 (0) 2 (33) 0 (0) 2 (18) 0 (0)
Deep vein thrombosis 0 (0) 1 (13) 0 (0) 1 (17) 2 (18) 0 (0)
Dehydration 0 (0) 0 (0) 1 (17) 0 (0) 3 (27) 0 (0)
Erythema 0 (0) 1 (13) 2 (33) 1 (17) 0 (0) 0 (0)
Patients with related AEs of speciﬁc
interest (all grades), n (%)
Venous thromboembolic events 0 (0) 2 (25) 3 (50) 2 (33) 3 (27) 0 (0)
Pulmonary embolism
Grade 4 0 (0) 0 (0) 2 (33) 2 (33)b 3 (27)c 0( 0 )
Grade 5 0 (0) 1 (13) 0 (0) 0 (0) 0 (0) 0 (0)
Deep vein thrombosis
Grade 2 0 (0) 1 (13) 0 (0) 0 (0) 0 (0) 0 (0)
Grade 3 0 (0) 0 (0) 0 (0) 1 (17)b 2 (18)c 0( 0 )
Jugular vein thrombosis
Grade 2 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 0 (0)
Arterial thromboembolic events 0 (0) 1 (13) 0 (0) 0 (0) 1 (9) 1 (50)
Arterial thrombosis
Grade 3 0 (0) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0)
Grade 4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (50)
Cerebrovascular accident
Grade 2 0 (0) 1 (13) 0 (0) 0 (0) 0 (0) 0 (0)
Other
Hemorrhagic eventsd
Grade 1 0 (0) 1 (13) 0 (0) 1 (17) 3 (27) 0 (0)
Gallbladder disorder
Grade 1 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 0 (0)
Neutropenia
Grade 3 0 (0) 1 (13) 0 (0) 0 (0) 0 (0) 0 (0)
AE: adverse event; BID: twice daily; QD: once daily.
aSudden death
bOne patient had grade 4 pulmonary embolism and grade 3 deep vein thrombosis.
cTwo patients had grade 4 pulmonary embolism and grade 3 deep vein thrombosis.
dIncludes epistaxis, gingival bleeding, hematemesis, hematochezia, and increased tendency to bruise.Journal of Oncology 7
Table 3: Pharmacokinetic parameter estimates (Mean±SD)a of motesanib after single-dose administration in combination with pani-
tumumab and gemcitabine/cisplatin.
Parameter Motesanib dose cohort
50mgQD
(n = 7 −8)
75mgQD
(n = 3 −6)
100mgQD
(n = 2 −4)
125mgQD
(n = 9 −11)
75mgBIDb
(n = 2)
tmax, h, median (range) 1 (1–3) 1 (1–3) 1.38 (1–3) 1 (1–3) 1 (1–1)
Cmax, ng/mL (SD) 152 (78) 186 (92) 278 (90) 458 (208) 268 (NR)
AUC0–24, µg·h/mL (SD) 1.03 (0.50) 1.31 (0.51) 2.38 (NR) 2.82 (1.02) 2.54 (NR)
AUC0–inf, µg·h/mL (SD) 1.12 (0.52) 1.64 (0.48) 2.59 (NR) 3.05 (1.34) NR
t1/2,z,h( S D ) 6.72 (0.71) 6.52 (2.00) 6.65 (NR) 6.28 (1.60) 5.21 (NR)
CL/F, L/h (SD) 51.1 (17.5) 48.8 (15.6) 38.6 (NR) 50.5 (27.5) 64.3 (NR)
C24, ng/mL (SD) 9.22 (2.85) 13.9 (6.7) 19.9 (NR) 31.0 (22.4) 143 (NR)
AUC0–inf: area under the plasma concentration-versus-time curve from time 0 to inﬁnite time; AUC0–24: area under the plasma concentration-versus-time
curve from time 0 to 24 hours after dose; BID: twice daily; CL/F: apparent clearance; Cmax: maximum observed concentration after dosing; C24:o b s e r v e d
concentration at 24 hours after dose; NR: not reported; QD: once daily; tmax: time of maximum observed plasma concentration; t1/2,z: estimated terminal
elimination half-life.
atmax values are reported as median (range).
bFor the 75-mgBID dose cohort, t1/2,z values were estimated based on the terminal slope after the ﬁrst dose on week 1 or 2, AUC0–24 values were estimated
using 2 ×AUC0–12, and CL/F was estimated by total daily dose/(2 ×AUC0–12).
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Figure 2: Mean plasma concentration-versus-time proﬁles of
motesanib following once- or twice-daily oral administration
in combination with panitumumab and gemcitabine/cisplatin
chemotherapy. Data are mean (±SD). aDiﬀerent n due to missing
or excluded values. BID: twice daily; QD: once daily.
cohorts except the 100-mgQD cohort. Plasma gemcitabine
concentrations on day 1 of cycle 1 in motesanib-treated
patients were generally similar to those observed in patients
in the dose cohort without motesanib. However, plasma
gemcitabine concentrations among patients in the 125-
mgQD cohort were slightly higher than those in the control
group (16100ng/mL versus 11000ng/mL). Similarly, mean
total and free platinum concentrations on day 1 of cycle 1
were generally similar in the dose cohort without motesanib
and in patients who received motesanib.
3.5. Eﬃcacy. Thirty-eight patients had measurable disease
at baseline. A conﬁrmed objective response was observed
in 10 patients (24%; 95% CI, 12.4–40.3). One patient
with breast cancer in the 125-mgQD dose cohort achieved
a complete response (treatment prior to enrollment into
the study included one line of capecitabine/docetaxel). Of
patients with conﬁrmed partial response (n = 9), ﬁve had
NSCLC (100-mgQD, n = 3, 75mgBID, and 125mgQD,
n = 1 each), two had pancreatic cancer (both in the 0-
mgQD cohort), one had bladder cancer (125mgQD), and
one had adenocarcinoma of unknown primary origin at
screening (75mgQD). None of these patients had received
any chemotherapy treatment prior to enrolling into the
study. Of the 10 patients with a conﬁrmed response, seven
were last known to be without progressive disease. Twenty
patients(49%)hadabestresponseofstabledisease.Ofthese,
six had durable (≥24 weeks) stable disease (Table 5). Of the
41 patients enrolled, 30 had either a complete response, or a
partial response, or stable disease as their best response. The
Kaplan-Meier estimate of median progression-free survival
was 28 weeks (95% CI: 2.8—not estimable).
4. Discussion
Inhibition of angiogenesis has been demonstrated to be a
tolerable and eﬀective treatment strategy for a variety of
diﬀerent solid tumors [4, 5]. Recent studies have suggested
that increased antitumor eﬃcacy can be achieved while
retaining acceptable toxicity by combining a VEGF inhibitor
with either cytotoxic chemotherapy [6, 22] or an EGFR
inhibitor [11, 12, 23, 24].
The primary objective of this dose escalation study was
to evaluate the safety of motesanib, an orally administered
small-molecule inhibitor of VEGFR1, 2, 3, PDGFR, and Kit
in combination with the fully human anti-EGFR antibody
panitumumab and gemcitabine/cisplatin in patients with
advanced solid tumors. Five patients in the 125-mgQD8 Journal of Oncology
Table 4: Mean concentrations of gemcitabine, platinum, and panitumumab.
Motesanib dose cohort
No
motesanib
(0mgQD)
50mgQD 75mgQD 100mgQD 125mgQD 75mgBID
Plasma gemcitabine concentration (cycle 1)
n 8866 1 1 2
Mean, ng/mL (SD) 11000 (4220) 8450 (7310) 14400 (6020) 6160 (3690) 16100 (6800) 8290 (NR)
Plasma platinum concentration (cycle 1)
n 8866 1 1 1
Mean total platinum, ng/mL (SD) 3580 (273) 2960 (730) 3630 (399) 3330 (536) 3560 (524) 3920 (NR)
Mean free platinum, ng/mL (SD)a 2190 (283) 1420 (924) 2250 (584) 1550 (321) 2140 (469) 2650 (NR)
Serum panitumumab concentration
Cycle 1
n 8765 1 1 2
Postdose mean concentration, µg/mL (SD) 206 (76.4) 174 (24.9) 158 (24.2) 194 (27.1) 203 (82.9) 189 (NR)
Cycle 2
n 676561
Predose mean concentration, µg/mL (SD) 11.2 (15.5) 9.0 (5.8) 13.1 (13.5) 18.9 (10.7) 13.4 (14.2) 11.2 (NR)
n 656461
Postdose mean concentration, µg/mL (SD) 186 (62.9) 193 (37.5) 194 (21.5) 224 (51.8) 213 (39.0) 217 (NR)
Cycle 4
n 435430
Predose mean concentration, µg/mL (SD) 56.5 (39.6) 10.5 (6.4) 32.5 (21.3) 41.6 (16.5) 21.7 (22.0) NR
n 336230
Postdose mean concentration, µg/mL (SD) 275 (118) 232 (52.8) 218 (26.1) 290 (NR) 170 (55.0) NR
BID: twice daily; NR: not reported; QD: once daily.
aMean free platinum concentrations are based on an assessment of platinum concentrations in plasma ultraﬁltrate.
Table 5: Best tumor response per modiﬁed RECIST as assessed by investigator.
Motesanib dose cohort
0mgQD
(n = 8)
50mgQD
(n = 8)
75mgQD
(n = 6)
100mgQD
(n = 6)
125mgQD
(n = 11)
75mgBID
(n = 2)
Patients with measurable disease
at baseline, n (%) 7 (88) 7 (88) 5 (83) 6 (100) 11 (100) 2 (100)
Response assessment, n (%)
Conﬁrmed complete responsea 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 0 (0)
Conﬁrmed partial response 2 (25) 0 (0) 1 (17) 3 (50) 2 (18) 1 (50)
Stable disease 4 (50) 5 (63) 4 (67) 2 (33) 4 (36) 1 (50)
Durable stable diseaseb 1 (13) 0 (0) 3 (50) 1 (17) 1 (9) 0 (0)
Progressive disease 1 (13) 2 (25) 0 (0) 0 (0) 1 (9) 0 (0)
Unevaluablec 0 (0) 0 (0) 1 (17) 0 (0) 1 (9) 0 (0)
Not done 1 (13) 1 (13) 0 (0) 0 (0) 3 (27) 0 (0)
Clinical beneﬁt rate
(CR+PR+durable SD) 6 (75) 5 (83) 5 (83) 6 (100) 6 (55) 2 (100)
Conﬁrmed objective response, %
(95% CId) 25 (3.2–65.1) 0 (0–36.9) 17 (0.4–64.1) 4 (22.3–95.7) 18 (2.3–51.8) 50 (1.3–98.7)
BID: twice daily; QD: once daily; RECIST: Response Evaluation Criteria in Solid Tumors.
aPatients with a response assessment of complete response or partial response that was not conﬁrmed within 4 weeks are reported as stable disease.
bDurable stable disease is deﬁned as stable disease with a duration of ≥24 weeks.
cUnevaluable includes patients with a response assessment of complete response, partial response, or stable disease before the scheduled ﬁrst assessment of
response without an additional assessment of response.
dBinomial proportion with exact 95% conﬁdence interval.Journal of Oncology 9
cohort experienced DLTs, and there was one sudden death
among patients receiving this dose. The patient incidence
of motesanib-related adverse events in general and, more
speciﬁcally, events commonly associated with VEGF(R)
inhibitortherapy,suchashypertensionorbleedingevents[5,
21, 25, 26], was comparable across dose cohorts and similar
to what has been reported in other motesanib monotherapy
and combination studies [14–16]. However, there was a high
incidence of thromboembolic events for the treatment regi-
men as a whole. Speciﬁcally, 10 patients (24%) had venous
thromboembolic events and three patients (7%) had arterial
thromboembolicevents(twoofwhomhadarterialthrombi).
The most frequently occurring thromboembolic events were
grade 4 pulmonary embolism (n = 8), grade 3 deep vein
thrombosis (n = 3), and grade 3/4 arterial thrombosis (n =
2). There was one grade 5 event of pulmonary embolism and
one sudden death in the 125-mgQD cohort, both of which
wereconsideredbytheinvestigatortoberelatedtomotesanib
treatment. In comparison, in a phase 2 study of the anti-
VEGF antibody bevacizumab plus carboplatin/paclitaxel in
patients with locally advanced or metastatic NSCLC the
patient incidence rate of thrombotic events was 17.6% in
the 15-mg/kg cohort (grade 3/4, n = 5) [27]. The adverse
event proﬁle observed in the present study indicates that
thecombinationtreatmentofmotesanib,panitumumab,and
gemcitabine/cisplatin at the doses and the schedule it was
administered is not tolerable. Consequently, Part 2 of the
study (which aimed to investigate eﬃcacy at the MTD) was
not enrolled.
The observation that this regimen is not tolerable is
consistent with recently published studies reporting that
combinations of VEGF inhibitors, EGFR inhibitors, and
cytotoxic chemotherapy may be diﬃcult to tolerate [28–30].
For example, in a study that investigated treatment with
bevacizumab plus erlotinib, 5-ﬂuorouracil, leucovorin, and
oxaliplatin (FOLFOX) in patients with metastatic colorectal
cancer 27 of the 35 patients (77%) who were enrolled
withdrew owing to protocol-deﬁned toxicity or intolerable
adverse eﬀects, including grade 3 rash, hospitalization for
febrile neutropenia, grade 3 nausea and emesis, and others
[31]. Speciﬁcally, adverse events leading to study withdrawal
included neurologic toxicity (six patients), small bowel
obstruction(twopatients),andothertoxicity(ninepatients).
Similarly, two phase 3 studies that assessed the combination
of chemotherapy, bevacizumab, and an anti-EGFR mono-
clonal antibody in patients with advanced metastatic col-
orectal cancer found that this combination did not improve
outcomes but was associated with exacerbated toxicity
compared with chemotherapy plus bevacizumab alone [28–
30]. In contrast, treatments that combine only one targeted
therapy and one cytotoxic chemotherapy appear to be
better tolerated. For example, treatment with motesanib plus
gemcitabine in patients with solid tumors showed accept-
able toxicity [19], while treatment with panitumumab in
combination with infusional 5-ﬂuorouracil has been shown
to be tolerable in patients with metastatic colorectal cancer
[32]. The utility of anti-VEGF/anti-EGFR/chemotherapy
combinations may be dependent upon both the setting and
the combination of agents investigated. Indeed, given that
administration of diﬀerent agents targeting similar signaling
pathways in combination with chemotherapy can result in
dissimilar outcomes [33, 34], it is likely that only a speciﬁc
anti-VEGF/anti-EGFR/chemotherapy combination will be
eﬀective against a particular tumor type. Consequently, it
remains possible that anti-VEGF/anti-EGFR/chemotherapy
combinations that have antitumor activity and acceptable
toxicity may yet be identiﬁed. It should be noted that anti-
VEGF/anti-EGFR/chemotherapy regimens are under further
investigation in more highly selected patient populations
such as those with NSCLC (SWOG-S0819 [NCT00946712]).
At present the mechanisms responsible for the increased
incidence of adverse events associated with anti-VEGF/anti-
EGFR/chemotherapy combinations are unknown. One plau-
sible explanation is that pharmacodynamic interactions
between the VEGF and EGF signaling pathways may result
in excess toxicity [35].
In the present study, the incidence of panitumumab-
related adverse events in the small group of patients
who received panitumumab in combination with only
gemcitabine/cisplatin (0-mg motesanib cohort) appeared
to be similar to that observed in previous panitumumab
monotherapy [36] and combination therapy studies [32,
37, 38]. The increased thrombogenicity may be related to
the cytotoxic doublet (gemcitabine/cisplatin) as observed in
other studies [39, 40].
There was no clear evidence of pharmacokinetic interac-
tions between motesanib, panitumumab, gemcitabine, and
cisplatin. Coadministration of panitumumab, gemcitabine,
and cisplatin did not result in increased exposure to mote-
sanib compared with monotherapy studies [14–16]. These
results suggest that there was no apparent trend of phar-
macokinetic interactions, given that motesanib is primarily
metabolized by glucuronidation and cytochrome P 450 3A-
mediated oxidation [41] and each of the other reagents is
metabolizedoreliminatedbyadiﬀerentmechanism[42–44].
The objective response rate of 24% and median
progression-free survival of 197 days observed in this study
suggest that the regimen of motesanib, panitumumab, and
gemcitabine/cisplatin may have some clinical beneﬁtin some
patients with advanced solid tumors. However, given the
observed safety signals, the relatively small size of the study
population, and the absence of a comparator group, it is
diﬃcult to interpret the data.
In conclusion, the MTD for motesanib in combination
with panitumumab and gemcitabine/cisplatin was estab-
lished at 100mgQD. However, there was a strong safety sig-
nal of thromboembolic events for the treatment regimen as
a whole. Overall, the combination could not be administered
consistently and, at the described doses and schedule, may
be intolerable to patients although encouraging antitumor
activity was noted in some patients.
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